Leukocell 2

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Feline leukemia virus

Disponible desde:

Zoetis UK Limited

Código ATC:

–QI06A

Designación común internacional (DCI):

Feline leukemia virus

formulario farmacéutico:

Solution for injection

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cats

Área terapéutica:

Inactivated Viral Vaccine

Estado de Autorización:

Authorized

Fecha de autorización:

2005-10-28

Ficha técnica

Revised: May 2020
AN: 00066/2020
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Leukocell 2
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (1ml) of Leukocell 2 contains the following
ACTIVE SUBSTANCES:
Inactivated sub-unit antigens (gp 70 and FOCMA) of feline leukaemia
virus (FeLV)
sub-types A, B and C: _minimum: 2266 ng/ml of gp70 antigen._
EXCIPIENTS:
Alhydrogel 2 % 50 μl
Quil A 25 μg
Thiomersal 0.115 mg (maximum)
See Section 6.1 for full list of excipients.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats from 9 weeks of age.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of cats to reduce persistent viraemia and lymphoid
tumours
caused by FeLV infection, and thereby to reduce other diseases
associated with
FeLV infection.
Onset of immunity occurs by approximately 3 weeks after the last dose
of the Basic
Vaccination Scheme.
The duration of immunity is at least 12 months.
4.3
CONTRAINDICATIONS
Unhealthy animals should not be vaccinated.
Revised: May 2020
AN: 00066/2020
Page 2 of 4
The
use
of
immunosuppressant
drugs
or
procedures
within
one
month
of
vaccination is contra-indicated.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
If an anaphylactic reaction occurs, institute treatment according to
the clinical signs
using adrenaline or other appropriate medication.
Vaccination is of no known clinical value in cats with pre-existing
FeLV infection, nor
will it change the natural course of the disease.
The effect of maternally derived antibodies (MDA) on the response to
vaccination is
not known, but on the basis of published data and field use it is
expected that the
levels of MDA that will be present at 9 weeks of age will not
interfere with the
response to vaccination.
4.5
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
None.
ii)
Special precautions to be taken by the person administering the
veterinary
medicinal product to animals
In case of accidental self-injection,